Douglas Miehm
Stock Analyst at RBC Capital
(3.23)
# 826
Out of 5,149 analysts
60
Total ratings
50%
Success rate
4.1%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNKD MannKind | Downgrades: Sector Perform | $7.5 → $3.5 | $2.93 | +19.66% | 5 | Feb 27, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $234 → $235 | $204.24 | +15.06% | 8 | Dec 10, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $17 → $19 | $17.98 | +5.67% | 14 | Nov 14, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Sector Perform | $9 → $15 | $14.15 | +6.01% | 11 | Nov 5, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $5.73 | +74.52% | 21 | May 2, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $1.04 | +380.77% | 1 | Mar 10, 2025 |
MannKind
Feb 27, 2026
Downgrades: Sector Perform
Price Target: $7.5 → $3.5
Current: $2.93
Upside: +19.66%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $234 → $235
Current: $204.24
Upside: +15.06%
Bausch + Lomb
Nov 14, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $17.98
Upside: +5.67%
Aurinia Pharmaceuticals
Nov 5, 2025
Downgrades: Sector Perform
Price Target: $9 → $15
Current: $14.15
Upside: +6.01%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $5.73
Upside: +74.52%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $1.04
Upside: +380.77%